Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 9/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | KLK7 | P49862 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12615516 | 0.82 | L3MBTL1 (0.42) | KDM4EUBE2NHTR6L3MBTL1ALK | |
| SCHEMBL31315845 | 0.81 | KDM4E (0.45) | KDM4EUBE2NHTR6L3MBTL1POLB | |
| SCHEMBL22128244 | 0.81 | KDM4E (0.45) | CA1CA2KDM4EUBE2NHTR6 | |
| SCHEMBL19611706 | 0.81 | HTR6 (0.49) | CA1CA2KDM4EUBE2NHTR6 | |
| SCHEMBL31315856 | 0.81 | KDM4E (0.45) | CA1CA2KDM4EUBE2NHTR6 | |
| SCHEMBL31315847 | 0.81 | KLK7 (0.48) | KDM4EUBE2NHTR6L3MBTL1CYP3A4 | |
| SCHEMBL31315848 | 0.80 | KDM4E (0.49) | CA1CA2KDM4EUBE2NHTR6 | |
| SCHEMBL31593168 | 0.80 | KDM4E (0.52) | KDM4EUBE2NHTR6L3MBTL1POLB | |
| SCHEMBL31315843 | 0.80 | KDM4E (0.52) | KDM4EUBE2NHTR6L3MBTL1POLB | |
| SCHEMBL31315854 | 0.79 | KDM4E (0.46) | CA1CA2KDM4EUBE2NHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10822342-B2 | Pyrazolopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-03 | — | — | US | disclosed |
| US-20190169198-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-06-06 | — | — | US | disclosed |
| US-10221180-B2 | Pyrazolopyrimidine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-03-05 | — | — | US | disclosed |
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20170334915-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20170334915-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | ARGENTA DISCOVERY 2009 LIMITED (GB) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169198-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K19 | CA1 4820/4885CA2 4776/4885KDM4E 1682/4885 |
| US-20170334900-A1 | NEW PYRAZOLE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K21 | CA1 4848/4885CA2 4835/4885KDM4E 2297/4885 |
| US-20170334915-A1 | NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, MAP3K15, MAP3K19 | CA1 4820/4885CA2 4776/4885KDM4E 1682/4885 |
| US-10822342-B2 | Pyrazolopyrimidine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | CA1 4815/4885CA2 4755/4885KDM4E 1536/4885 |
| US-10221180-B2 | Pyrazolopyrimidine derivatives as NIK inhibitors | MAP3K14, MAP3K15, MAP3K12 | CA1 4815/4885CA2 4755/4885KDM4E 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.